Who has all the NK, CAR-T, Check point, targeted chemical candidates? And how much does it cost for you to buy them all? 1/15! comparing to FBIO, NK is expensive.
2015_05_27's change, you can see how many deletions are there. Don't forget to uncheck "Hide non-essential portions"
It's like an XML files compare.
If you check the update status of celestial, you may find something interesting. After 2014_10_27, they suddenly stopped updating for half year. That was normal behavior like before then. And then finally came out saying that clinical trial sites amount was cut. It sounds like they slow down enrollment after the big layoff.
cabo is directly compete with sunitinib, especially after cabosun and celestial. And buying out cabo won't give it any synergy. Sutent's more than one billion market will erode fast next year.
Will the number 259 be adjusted according to drop out rate, or be fixed at that? If 259 is rigid, this number will take long time to reach with a 15% drop out rate.
Kinda agree. Some patients on some forum express the same idea. cabo works, but with strong se. It needs better result to take over other TKI's market. Don't know if the dropout has effect on meteor cut-off date.
That's easy. At GILD, he was working under CFO. Here in EXEL, he is CFO, and CEO is an idiot about finance.
They already have the estimated result at hand. It's easy to find out the answer from very raw data. But the result is not clean enough to do a release. The time window for complete analysis is too long for any companies.
It might not be appropriate to talk about other companies here. It's FBIO, changed name from CNDO, and changed its business model. Is it viable to partner with some research institutes and get some promising junks, let the government verify them and sell?